Company news
CAMP4 Therapeutics Corporation news in 2026
CAMP4 Therapeutics Corporation's news releases, calls and decks from 2026, newest first.
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 17, 2026
CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights
November 5, 2026
CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
October 27, 2026
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
September 10, 2026
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
September 8, 2026
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
August 13, 2026
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
August 4, 2026
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
July 27, 2026
CalAmp Expands Remote Monitoring Support for Modbus-Enabled Specialty Equipment
July 16, 2026
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
May 14, 2026
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
May 7, 2026
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
April 28, 2026
Calamos Brings Award-Winning Autocallable Income ETF Strategy to Global Investors with Launch of World's First Autocallable UCITS ETF
April 27, 2026
CAMP4 Appoints Michael MacLean to its Board of Directors
March 24, 2026
CAMP4 Appoints Michael MacLean to its Board of Directors
March 24, 2026
CAMP4 to Participate in Upcoming Investor Conferences
March 6, 2026
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
March 5, 2026
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
Decks in 2026
- Investor Day (September 2026)
Investor day · 30 slides · Sep 28, 2026
- Investor Presentation (September 2026)
Investor deck · 26 slides · Sep 28, 2026
- Investor Presentation (May 2026)
Investor deck · 21 slides · May 14, 2026
- Investor Presentation (March 2026)
Investor deck · 22 slides · Mar 5, 2026
- Investor Presentation (January 2026)
Investor deck · 22 slides · Jan 9, 2026